RT @coughlin582: Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https…
RT @coughlin582: Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https…
RT @coughlin582: Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https…
RT @AdilDaud3: Thanks @coughlin582 ! Adding a paper from James Lee and @kickassscience1 declining into the mechanism https://t.co/nGgNfMRb1…
Thanks @coughlin582 ! Adding a paper from James Lee and @kickassscience1 declining into the mechanism https://t.co/nGgNfMRb1x
RT @coughlin582: Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https…
RT @coughlin582: Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https…
Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here. https://t.co/JR4ZJTddyk https://t.co/v45ouqLyQF
Liver mets predict poor PD1 outcome. CTLA4hi Treg mechnism w/inductn of MDSC. #immunotherapy https://t.co/o1JgbXMtpD https://t.co/JR4ZJTddyk
RT @ad1600: The original observation was made in 2017 https://t.co/xTQ5iNTfAp
wow. I was just looking up this study as it was one of the references on Dr. @mgfakih poster 495P at ESMO 2020 If you wonder if there is a God, apparently He is on twitter (and PubMed, of course).
The original observation was made in 2017 https://t.co/xTQ5iNTfAp
Interesting... poor outcomes with hepatic mets and immuno (shown in melanoma). Could this change OS in many cancers with hepatectomy. XRT coud replace hepatic surgery... What say thee @KlempnerSam @angelesclinic https://t.co/AtyGL89J5v
Liver Metastasis and Treatment Outcome with Anti-PD-1 "...liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS" https://t.co/0n89JCWlzJ
RT @alexshoushtari: @mcquadeMDLAc @ahmadalhader @ATarhiniMDPhD @jasonlukemd Also shoutout to @ad1600 @katyktsai and others for their work i…
RT @alexshoushtari: @mcquadeMDLAc @ahmadalhader @ATarhiniMDPhD @jasonlukemd Also shoutout to @ad1600 @katyktsai and others for their work i…
@mcquadeMDLAc @ahmadalhader @ATarhiniMDPhD @jasonlukemd Also shoutout to @ad1600 @katyktsai and others for their work in investigating how liver met microenvironment may be immunologically predisposed to PD-1 resistance: https://t.co/m9GnUxxaiz
RT @ad1600: our data provide a mechanistic explanation, reduced T cell infiltration https://t.co/n2vOrsQjAd @JCI_insight. lower partially…
RT @ad1600: our data provide a mechanistic explanation, reduced T cell infiltration https://t.co/n2vOrsQjAd @JCI_insight. lower partially…
our data provide a mechanistic explanation, reduced T cell infiltration https://t.co/n2vOrsQjAd @JCI_insight. lower partially exhausted CTL in women. https://t.co/gCdEanzLQx. @UCSF. related to parity? https://t.co/lpAvmCtF3S
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. https://t.co/53dgc57wiu
Si happy to be part of this project, take a look! https://t.co/4CZPkuwTxU
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC https://t.co/EEv05kzV0L
RT @champiatMD: Lower efficacy of anti-PD1 in liver metastatic Melanoma & NSCLC https://t.co/khlvYYnBME
Lower efficacy of anti-PD1 in liver metastatic Melanoma & NSCLC https://t.co/khlvYYnBME
RT @immuno_onc: Liver Metastasis and Treatment Outcome with anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. https://t.co…
Liver Metastasis and Treatment Outcome with anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. https://t.co/DGUuRKA21T https://t.co/kcgoVSh1o4